GlassScriptPhysician profile
Tamara L Bennett
NPI 1154494383
$7,452.26
in general payments reported to CMS, 2019-2025
41 companies · $1,763 in 2025
The $1,763 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $881 · 2022: $1,067 · 2023: $1,865 · 2024: $1,876 · 2025: $1,763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,445 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,445.00 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $817.25 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Lilly USA, LLC | $788.91 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $749.52 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $513.05 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Insulet Corporation | $502.15 | 2021-2025 | Omnipod |
| Abbott Laboratories | $372.16 | 2021-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $365.25 | 2021-2023 | |
| Cequr Corporation | $359.19 | 2023-2025 | Cequr Simplicity |
| Mannkind Corporation | $285.24 | 2023-2025 | Afrezza |
| Xeris Pharmaceuticals, INC. | $282.09 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Medtronic, INC. | $273.83 | 2021-2025 | Minimed 780g, Inceptiv |
| Corcept Therapeutics | $218.76 | 2023-2025 | Korlym |
| Tandem Diabetes Care, INC. | $178.30 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Intra-Sana Laboratories | $177.11 | 2023-2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Abbvie INC. | $171.90 | 2023-2025 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $171.56 | 2023-2025 | Tepezza, Prolia, Prolia |
| Astrazeneca Pharmaceuticals LP | $138.31 | 2021-2022 | |
| Beta Bionics, INC. | $128.19 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Pfizer INC. | $110.50 | 2022-2025 | |
| Averitas Pharma INC. | $86.83 | 2024-2025 | Qutenza |
| Zealand Pharma US, INC. | $74.97 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.86 | 2024 | |
| Ibsa Pharma INC. | $62.43 | 2023-2025 | Tirosint, Licart, Flector |
| Esperion Therapeutics, INC. | $53.84 | 2024-2025 | Nexletol |
| Janssen Scientific Affairs, LLC | $50.55 | 2023 | Xarelto |
| Alexion Pharmaceuticals, INC. | $49.58 | 2024-2025 | Strensiq |
| Chiesi USA, INC. | $47.05 | 2025 | Juxtapid, Mycapssa |
| Ascendis Pharma Endocrinology INC | $45.54 | 2023-2025 | Yorvipath |
| Daiichi Sankyo INC. | $36.82 | 2023 | Injectafer |
| Sequel Med Tech, LLC | $35.20 | 2025 | Twiist |
| Madrigal Pharmaceuticals | $31.88 | 2024-2025 | Resmetirom, Rezdiffra |
| Horizon Therapeutics Plc | $24.55 | 2023 | Tepezza |
| Eusa Pharma (US) LLC | $24.03 | 2022 | |
| Recordati_rare_diseases_inc. | $24.02 | 2022 | |
| Lifescan, INC. | $22.84 | 2022 | |
| Nevro Corp. | $21.02 | 2023 | Senza |
| Kyowa Kirin, INC. | $20.77 | 2023 | |
| Vistapharm, INC. | $20.53 | 2021 | |
| Neurocrine Biosciences, INC. | $18.75 | 2024 | |
| Soleno Therapeutics, INC. | $16.44 | 2025 | Vykat Xr |
| Echosens North America, INC. | $15.49 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.